Yao, Zhan
Gao, Yijun
Su, Wenjing
Yaeger, Rona
Tao, Jessica
Na, Na
Zhang, Ying
Zhang, Chao
Rymar, Andrey
Tao, Anthony
Timaul, Neilawattie M.
Mcgriskin, Rory
Outmezguine, Nathaniel A.
Zhao, HuiYong
Chang, Qing
Qeriqi, Besnik
Barbacid, Mariano
de Stanchina, Elisa
Hyman, David M http://orcid.org/0000-0001-8150-9762
Bollag, Gideon
Rosen, Neal http://orcid.org/0000-0002-8307-654X
Article History
Received: 26 December 2017
Accepted: 9 October 2018
First Online: 17 December 2018
Competing interests
: N.R. is on the scientific advisory board (SAB) and receives research funding from Chugai, on the SAB and owns equity in Beigene, and Fortress. N.R. is also on the SAB of Daiichi-Sankyo, Astra-Zeneca-MedImmune, and F-Prime, and is a past SAB member of Millenium-Takeda, Kadmon, Kura, and Araxes. N.R. is a consultant to Novartis, Boehringer Ingelheim, Tarveda, and Foresight and consulted in the last three years with Eli Lilly, Merrimack, Kura Oncology, Araxes, and Kadman. N.R. owns equity in ZaiLab, Kura Oncology, Araxes, and Kadman. N.R. collaborates with Plexxikon. R.Y. has received research support from Array BioPharma, Genentech, GlaxoSmithKline, and Norvatis; received travel expenses from Array BioPharma; and served on the advisory board for GlaxoSmithKline. D.M.H. has consulted for Atara Biotherapeutics, Chugai Pharma, CytomX Therapeutics, Boehringer Ingelheim, AstraZeneca, Pfizer, Bayer, Debiopharm Group, and Genetech and has received research funding from AstraZeneca, Puma Biotechnology, and Loxo Oncology. Y.Z., C.Z., A.R., and G.B. are employees of Plexxikon Inc.